Provided by Tiger Fintech (Singapore) Pte. Ltd.

Nektar Therapeutics

44.33
+4.1510.33%
Pre-market: 44.540.2100+0.47%07:11 EDT
Volume:1.97M
Turnover:83.91M
Market Cap:843.09M
PE:-4.66
High:44.33
Open:40.71
Low:39.10
Close:40.18
52wk High:44.33
52wk Low:6.48
Shares:19.02M
Float Shares:16.64M
Volume Ratio:1.52
T/O Rate:11.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-9.5163
EPS(LYR):-8.6765
ROE:-440.80%
ROA:-31.57%
PB:-34.82
PE(LYR):-5.11

Loading ...

Nektar Therapeutics to Present Promising Phase 2b Results for Rezpegaldesleukin in Atopic Dermatitis at EADV 2025 Congress

Reuters
·
12 mins ago

Nektar Announces Rezolve-Ad Phase 2B Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at Eadv 2025

THOMSON REUTERS
·
15 mins ago

Chief R&D Officer Jonathan Zalevsky Reports Disposal of Common Shares of Nektar Therapeutics

Reuters
·
10 hours ago

Nektar Therapeutics CEO Howard W. Robin Reports Disposal of Common Shares

Reuters
·
10 hours ago

Why Nektar Therapeutics Rippled Higher This Week

Motley Fool
·
Sep 06

Jonathan Zalevsky, Chief R&D Officer, Reports Disposal of Nektar Therapeutics Common Shares

Reuters
·
Sep 05

Nektar Therapeutics CEO Howard W. Robin Reports Disposal of Common Shares

Reuters
·
Sep 05

What's Going On With Nektar Therapeutics Stock On Thursday?

Benzinga
·
Sep 05

Nektar Therapeutics to Webcast Participation in H.C. Wainwright Global Investment Conference and Stifel Virtual Immunology Forum

Reuters
·
Sep 04

Chief R&D Officer Jonathan Zalevsky Reports Disposal of Common Shares of Nektar Therapeutics

Reuters
·
Aug 22

Nektar Therapeutics President & CEO Howard W. Robin Reports Disposal of Common Shares

Reuters
·
Aug 22

Nektar Therapeutics : Oppenheimer Raises Target Price to $98 From $90

THOMSON REUTERS
·
Aug 08

Nektar Therapeutics reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 08

Nektar Therapeutics Q2 EPS $(2.95) Misses $(2.92) Estimate, Sales $11.18M Beat $10.84M Estimate

Benzinga
·
Aug 08

Nektar Therapeutics Q2 Product Sales USD 11.175 Million

THOMSON REUTERS
·
Aug 08

Nektar Therapeutics to Announce Financial Results for the Second Quarter

Reuters
·
Aug 01

FDA Grants Fast Track Designation to Nektar Therapeutics' Rezpegaldesleukin for Severe Alopecia Areata Treatment

Reuters
·
Jul 29

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata

THOMSON REUTERS
·
Jul 29

Nektar Therapeutics Is Maintained at Buy by B. Riley Securities

Dow Jones
·
Jul 09

U.S. RESEARCH ROUNDUP-Hershey, Metlife, Voya Financial

Reuters
·
Jul 08